BioSpace News Archive

Orion obtains rights to commercialize both the oral and IV franchises of ganaxolone in Europe. Collaboration supports mid-2022 European launch of oral ganaxolone for CDKL5 deficiency disorder, if approved; leverages Orion’s expertise in rare orphan diseases, antiepileptics and European commercialization

Acerus Pharmaceuticals Corporation will announce its second quarter 2021 financial and operating results on Tuesday, August 10, 2021 before the market opens.

Generation Bio Co. announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a panel discussion at the Wedbush PacGrow Healthcare Conference 2021 on Tuesday, August 10 at 9:10 a.m. ET.

Titan Medical Inc. today announced that the company plans to issue its second quarter 2021 financial results prior to market opening on Wednesday, August 11, 2021.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held August 9-10 2021.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced the promotions of Jason Okazaki to chief operating officer and Michael Samar to chief financial officer.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the second quarter ended June 30, 2021 after the market close on Thursday, August 12, 2021.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today reported financial results for the second quarter and six months ended June 30, 2021.

111, Inc. (“111" or the “Company”) (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced a strategic cooperation agreement with Suzhou Zelgen Biopharmaceuticals Co., Ltd. (“Zelgen”) (688266.SH), an innovative drug R&D and production company.

Amyris, Inc. today announced that John Melo , President and Chief Executive Officer, will present at the Oppenheimer 24th Annual Technology Conference.